JEFFREY ELFENBEIN: Open Payments
NPI 1043308695 · SEAFORD, NY. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,094 in 55 payments from 14 companies in 2025. Trend: 2023 $3,129 · 2024 $1,950 · 2025 $1,094
Food & beverage: $1,094
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 21 | $414 |
| PFIZER INC. | 8 | $138 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 5 | $124 |
| AstraZeneca Pharmaceuticals LP | 4 | $80 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 3 | $56 |
| GlaxoSmithKline, LLC. | 3 | $52 |
| Boston Scientific Corporation | 2 | $46 |
| Lilly USA, LLC | 2 | $44 |
| MEDICOMP INC | 2 | $39 |
| Novo Nordisk Inc | 1 | $25 |
Products named: QULIPTA, JARDIANCE, PREVNAR 20, UBRELVY, XIFAXAN, TRELEGY ELLIPTA, FARXIGA, WATCHMAN FLX.
Industry payments across NY — which companies pay providers there.
